ScholarWorks@Gyeongsang National University

Browsing by Kim, Jin-SooAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 12 of 12

SCIESCOPUS
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitorsopen access

Cho, Byoung Chul; Han, Ji-Youn; Kim, Sang-We; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok, et al.

ArticleIssue Date2022CitationJOURNAL OF THORACIC ONCOLOGY, v.17, no.4, pp 558 - 567PublisherELSEVIER SCIENCE INC
SCIESCOPUS
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutationsopen access

Park, Keunchil; Kim, Jin-Soo; Kim, Joo-Hang; Kim, Young-Chul; Kim, Hoon-Gu; Cho, Eun Kyung; Jin, Jong-Youl; Kim, Miyoung; Marten, Angela; Kang, Jin-Hyoung

ArticleIssue Date2021CitationBMC CANCER, v.21, no.1PublisherBMC
SCIESCOPUS
Antioxidant activities of phlorotannins purified from Ecklonia cava on free radical scavenging using ESR and H2O2-mediated DNA damage

Ahn, Gin-Nae; Kim, Kil-Nam; Cha, Seon-Heui; Song, Choon-Bok; Lee, Jehee; Heo, Moon-Soo; Yeo, In-Kyu; Lee, Nam-Ho; Jee, Young-Heun; Kim, Jin-Soo, et al.

ArticleIssue Date2007CitationEUROPEAN FOOD RESEARCH AND TECHNOLOGY, v.226, no.1-2, pp 71 - 79PublisherSPRINGER
SCIESCOPUS
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

Han, Ji-Youn; Ahn, Myung-Ju; Kim, Sang-We; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won, et al.

ArticleIssue Date2020CitationJournal of Clinical Oncology, v.38, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUS
Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trialopen access

Lee, Kyung-Hee; Kim, Tae Won; Kang, Jung-Hun; Kim, Jin-Soo; Ahn, Jin-Seok; Kim, Sun-Young; Yun, Hwan-Jung; Eum, Young-Jun; Koh, Sung Ae; Kim, Min Kyoung, et al.

ArticleIssue Date2017CitationCHINESE JOURNAL OF CANCER, v.36PublisherSUN YAT SEN UNIV MED SCI WHO
SCIESCOPUS
Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

Lee, Ki Hyeong; Ahn, Myung-Ju; Han, Ji-Youn; Kim, Sang-We; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won, et al.

ArticleIssue Date2020CitationJournal of Clinical Oncology, v.38, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUS
Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.

Kim, Sang-We; Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Cho, Eun Kyung; Lee, Yun-Gyoo; Kim, Dong-Wan; Kim, Joo-Hang; Lee, Jong-Seok; Lee, Gyeong-Won, et al.

ArticleIssue Date2020CitationJournal of Clinical Oncology, v.38, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUS
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Ahn, Myung-Ju; Han, Ji-Youn; Lee, Ki Hyeong; Kim, Sang-We; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Kim, Joo-Hang; Lee, Gyeong-Won; Lee, Jong-Seok, et al.

ArticleIssue Date2019CitationLANCET ONCOLOGY, v.20, no.12, pp 1681 - 1690PublisherELSEVIER SCIENCE INC
SCIESCOPUSKCI
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

Lee, Ki Hyeong; Cho, Byoung Chul; Ahn, Myung-Ju; Lee, Yun-Gyoo; Lee, Youngjoo; Lee, Jong-Seok; Kim, Joo-Hang; Min, Young Joo; Lee, Gyeong-Won; Lee, Sung Sook, et al.

ArticleIssue Date2024CitationCancer Research and Treatment, v.56, no.1, pp 48 - 60Publisher대한암학회
SCISCIESCOPUS
Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.

Ahn, Myung-Ju; Han, Ji-Youn; Kim, Sang-We; Lee, Ki Hyeong; Kim, Dong-Wan; Lee, Yun-Gyoo; Cho, Eun Kyung; Lee, Gyeong-won; Lee, Jong-Seok; Kim, Joo-Hang, et al.

ArticleIssue Date2019CitationJournal of Clinical Oncology, v.37, no.15PublisherAmerican Society of Clinical Oncology
SCIESCOPUSKCI
Randomized Phase III Trail of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Canceropen access

Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; Park, Keunchil; Kim, Hoon-Kyo; Jang, Joung Soon; Kim, Bong-Seog; Kang, Jin-Hyoung; Lee, Kyung Flee; Kim, Sang-We, et al.

ArticleIssue Date2019CitationCANCER RESEARCH AND TREATMENT, v.51, no.1, pp 119 - 127PublisherKOREAN CANCER ASSOCIATION
SCISCIESCOPUS
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

Kim, Dong-Wan; Lee, Dae Ho; Han, Ji-Youn; Lee, Jongseok; Cho, Byoung Chul; Kang, Jin Hyoung; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Jin-Soo; Min, Young Joo, et al.

ArticleIssue Date2019CitationLung Cancer, v.135, pp 66 - 72PublisherElsevier BV
1
CONTACT US

RSS_1.0 RSS_2.0 ATOM_1.0

Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0533

COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어